Translating clinical activity and gene expression signatures of etanercept and ciclosporin to the psoriasis xenograft SCID mouse model

British Journal of Dermatology

Volumn 166, Issue 3, 2012, Pages 649-652

  Norsgaard, H ^a   Svensson, L ^a   Hagedorn, P H ^a   Moller, K ^a   Olsen, G M ^a   Labuda, T ^a  

^a LEO PHARMA A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CYCLOSPORIN A; ETANERCEPT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL PROLIFERATION; DRUG ACTIVITY; EPIDERMIS HYPERPLASIA; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SCID MOUSE; XENOGRAFT;

ANIMALS; BIOLOGICAL MARKERS; CHEMOKINES; CYCLOSPORINE; CYTOKINES; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; DOWN-REGULATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOGLOBULIN G; MICE; MICE, SCID; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; TRANSPLANTATION, HETEROLOGOUS;

EID: 84857523101     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2011.10713.x     Document Type: Article

References (15)

1. Boehncke WH, Dressel D, Zollner TM, Kaufmann R,. Pulling the trigger on psoriasis. Nature 1996; 379: 777.
2. Boehncke WH, Zollner TM, Dressel D, et al. Induction of psoriasiform inflammation by a bacterial superantigen in the SCID-hu xenogeneic transplantation model. J Cutan Pathol 1997; 24: 1-7. (Pubitemid 27060070)
3. Wrone-Smith T, Nickoloff BJ,. Dermal injection of immunocytes induces psoriasis. J Clin Invest 1996; 98: 1878-87. (Pubitemid 26359206)
4. Kvist PH, Svensson L, Hagberg O, et al. Comparison of the effects of vitamin D products in a psoriasis plaque test and a murine psoriasis xenograft model. J Transl Med 2009; 7: 107.
5. Jakobsen M, Stenderup K, Rosada C, et al. Amelioration of psoriasis by anti-TNF-alpha RNAi in the xenograft transplantation model. Mol Ther 2009; 17: 1743-53.
6. Stenderup K, Rosada C, Worsaae A, et al. Interleukin-20 plays a critical role in maintenance and development of psoriasis in the human xenograft transplantation model. Br J Dermatol 2009; 160: 284-96.
7. Zeigler M, Chi Y, Tumas DB, et al. Anti-CD11a ameliorates disease in the human psoriatic skin-SCID mouse transplant model: comparison of antibody to CD11a with cyclosporin A and clobetasol propionate. Lab Invest 2001; 81: 1253-61. (Pubitemid 32911974)
8. Stenderup K, Rosada C, Dam TN, et al. Resolution of psoriasis by a leukocyte-targeting bacterial protein in a humanized mouse model. J Invest Dermatol 2011; 131: 2033-9.
9. Bak RO, Stenderup K, Rosada C, et al. Targeting of human interleukin-12B by small hairpin RNAs in xenografted psoriatic skin. BMC Dermatol 2011; 11: 5.
10. Haider AS, Lowes MA, Suarez-Farinas M, et al. Identification of cellular pathways of "type 1", Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis. J Immunol 2008; 180: 1913-20.
11. Zaba LC, Suarez-Farinas M, Fuentes-Duculan J, et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 2009; 124: 1022-10.e1-395.
12. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007; 204: 3183-94.
13. Sugai J, Iizuka M, Kawakubo Y, et al. Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci 1998; 17: 85-92. (Pubitemid 28294258)
14. Boyman O, Hefti HP, Conrad C, et al. Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha. J Exp Med 2004; 199: 731-6. (Pubitemid 38316440)
15. Ma HL, Napierata L, Stedman N, et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010; 62: 430-40.